Aileron Therapeutics (ALRN) News Today $4.12 +0.27 (+7.01%) (As of 10/31/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for RetinoblastomaOctober 31 at 7:30 AM | prnewswire.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Declines By 14.2%October 29 at 3:00 AM | americanbankingnews.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest UpdateAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 297,800 shares, an increase of 15.8% from the September 15th total of 257,100 shares. Based on an average daily volume of 66,100 shares, the days-to-cover ratio is presently 4.5 days. Currently, 1.5% of the company's stock are sold short.October 14, 2024 | marketbeat.comAileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway FibrosisOctober 12, 2024 | prnewswire.comAileron Therapeutics (NASDAQ:ALRN) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comUniversity of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN)University of Texas Texas AM Investment Management Co. purchased a new stake in Aileron Therapeutics, Inc. (NASDAQ:ALRN - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,777,827 shares ofOctober 2, 2024 | marketbeat.comNantahala Capital Management LLC Raises Stock Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN)Nantahala Capital Management LLC boosted its holdings in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN - Free Report) by 82.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 464,367 shares of the companOctober 1, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in SeptemberAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) was the recipient of a large decline in short interest in September. As of September 15th, there was short interest totalling 257,100 shares, a decline of 13.4% from the August 31st total of 296,800 shares. Based on an average daily volume of 82,900 shares, the days-to-cover ratio is currently 3.1 days. Currently, 1.3% of the company's stock are sold short.September 28, 2024 | marketbeat.comAileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)September 23, 2024 | prnewswire.comUniversity of Texas Texas AM Investment Management Co. Makes New Investment in Aileron Therapeutics, Inc. (NASDAQ:ALRN)University of Texas Texas AM Investment Management Co. purchased a new position in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,777,827 shares ofSeptember 3, 2024 | marketbeat.comAileron Therapeutics reports voting results from annual meetingAugust 24, 2024 | investing.comAileron Therapeutics to Present at the 8th Annual IPF SummitAugust 19, 2024 | prnewswire.comAileron Therapeutics, Inc.: Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 15, 2024 | finanznachrichten.deAileron Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 14, 2024 | prnewswire.comAileron Therapeutics Inc (ALRN)August 10, 2024 | investing.comAileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceJuly 30, 2024 | prnewswire.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Growth in Short InterestAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 272,900 shares, an increase of 94.4% from the June 15th total of 140,400 shares. Based on an average daily volume of 117,000 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.4% of the company's stock are short sold.July 12, 2024 | marketbeat.comAileron Therapeutics to be Included in the Russell Microcap® IndexJuly 1, 2024 | prnewswire.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Decreases By 41.3%Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 140,400 shares, a decline of 41.3% from the May 31st total of 239,200 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average daily volume of 110,200 shares, the short-interest ratio is presently 1.3 days.June 28, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Of Texas/Texas Am I. University Sells 4,707 SharesJune 18, 2024 | insidertrades.comOf Texas/Texas Am I. University Sells 9,342 Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) StockJune 13, 2024 | insidertrades.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 9,577 Shares of StockJune 13, 2024 | insidertrades.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 6,291 Shares of StockJune 8, 2024 | insidertrades.comAileron Therapeutics (NASDAQ:ALRN) Rating Increased to Strong-Buy at Brookline Capital ManagementBrookline Capital Management upgraded shares of Aileron Therapeutics to a "strong-buy" rating in a research note on Thursday.June 1, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Increase in Short InterestAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 256,900 shares, an increase of 89.0% from the April 30th total of 135,900 shares. Approximately 1.3% of the company's stock are sold short. Based on an average daily trading volume, of 90,500 shares, the days-to-cover ratio is presently 2.8 days.May 29, 2024 | marketbeat.comAileron Therapeutics (NASDAQ:ALRN) Releases Earnings Results, Misses Expectations By $0.72 EPSAileron Therapeutics (NASDAQ:ALRN - Get Free Report) released its earnings results on Monday. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.72).May 21, 2024 | marketbeat.comAileron Therapeutics, Inc.: Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 16, 2024 | finanznachrichten.deALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024May 15, 2024 | msn.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | tmcnet.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | globenewswire.comAileron Therapeutics to Present at Two Upcoming Investor ConferencesMay 6, 2024 | globenewswire.comALRN Aileron Therapeutics, Inc.May 3, 2024 | seekingalpha.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 3, 2024 | finance.yahoo.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 3, 2024 | globenewswire.comAileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trialMay 2, 2024 | finance.yahoo.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 10,746 Shares of StockMay 2, 2024 | insidertrades.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells $53,192.70 in StockAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the company's stock in a transaction on Monday, April 29th. The shares were sold at an average price of $4.95, for a total value of $53,192.70. Following the completion of the transaction, the insider now owns 1,799,711 shares of the company's stock, valued at approximately $8,908,569.45. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.May 1, 2024 | marketbeat.comAileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionMay 1, 2024 | globenewswire.comAileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)May 1, 2024 | globenewswire.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Rises By 22.9%Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 43,400 shares, an increase of 22.9% from the March 31st total of 35,300 shares. Based on an average daily volume of 65,900 shares, the short-interest ratio is presently 0.7 days. Approximately 0.3% of the company's shares are sold short.April 28, 2024 | marketbeat.comTrading was temporarily halted for "ALRN" at 09:04 AM with a stated reason of "LULD pause."April 18, 2024 | marketbeat.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023April 16, 2024 | investorplace.comAileron Therapeutics, Inc.: Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 16, 2024 | finanznachrichten.deAileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 15, 2024 | globenewswire.comAileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor ReplacementMarch 12, 2024 | markets.businessinsider.comAileron Therapeutics Announces CEO TransitionMarch 12, 2024 | globenewswire.comTrading was temporarily halted for "ALRN" at 09:02 AM with a stated reason of "LULD pause."February 28, 2024 | marketbeat.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 15, 2024 | finance.yahoo.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 15, 2024 | globenewswire.comAileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024February 1, 2024 | finance.yahoo.com Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip? Click Here to learn how to get in now >>> ALRN Media Mentions By Week ALRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALRN News Sentiment▼1.190.68▲Average Medical News Sentiment ALRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALRN Articles This Week▼41▲ALRN Articles Average Week Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PDS Biotechnology News Unity Biotechnology News Cumberland Pharmaceuticals News Zevra Therapeutics News Amylyx Pharmaceuticals News YS Biopharma News Jasper Therapeutics News Lexeo Therapeutics News biote News Aurora Cannabis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALRN) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
